Postpartum depression

Human brain
#Mergers and acquisitions #Neuropsychiatric disorders #Neuroscience #Postpartum depression #Sage Therapeutics #Supernus Pharmaceuticals

Supernus acquires Sage to strengthen neuropsychiatry portfolio

Supernus Pharmaceuticals will acquire Sage Therapeutics through a tender offer totalling approximately $795 million.  The transaction will provide Supernus with Zurzuvae (zuranolone) capsules CIV, the only US Food and Drug Administration (FDA)-approved oral medicine indicated for the treatment of adults with postpartum depression.  Through a collaboration agreement with Biogen, Supernus… Read More

#Business & Investment #News #Trending News

World Mental Health Day
#Depression #Drug discovery #Major depressive disorder #Mental health #Postpartum depression

World Mental Health Day 2023: Drug discovery breakthroughs

Over recent months, there have been a number of ground-breaking discoveries in drug discovery for mental health conditions. A new class of antidepressants In July 2023, AlzeCure Pharma published the results of a preclinical study supporting the antidepressive effects ACD856, the first in a new class… Read More

#Editor's Choice #News

Patient speaking to psychiatrist
#FDA #Mental health #Postpartum depression #Sage Therapeutics

First oral drug for postpartum depression approved in US

The US Food and Drug Administration (FDA) has approved Sage Therapeutics’ Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. Until now, treatment for PPD was only available as an IV injection given by a health care provider in certain health care facilities. “Postpartum depression… Read More

#News #Regulatory

#Anxiety disorder #Biotherapeutics #Neuroscience #Postpartum depression

Potential treatment for anxiety and postpartum depression 

PureTech Health, a clinical-stage biotherapeutics company, will advance therapeutic candidate LYT-300 (oral allopregnanolone) for the potential treatment of anxiety disorders and postpartum depression (PPD).    A social anxiety clinical trial in healthy volunteers is expected to begin in the first half of 2023, with results anticipated by the… Read More

#News